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Abstract
Background: Cell-free foetal haemoglobin (HbF) has been shown to play a role in the pathology of preeclampsia (PE). In the
present study, we aimed to further characterize the harmful effects of extracellular free haemoglobin (Hb) on the placenta.
In particular, we investigated whether cell-free Hb affects the release of placental syncytiotrophoblast vesicles (STBMs) and
their micro-RNA content.
Methods: The dual ex-vivo perfusion system was used to perfuse isolated cotyledons from human placenta, with medium
alone (control) or supplemented with cell-free Hb. Perfusion medium from the maternal side of the placenta was collected
at the end of all perfusion phases. The STBMs were isolated using ultra-centrifugation, at 10,0006g and 150,0006g (referred
to as 10K and 150K STBMs). The STBMs were characterized using the nanoparticle tracking analysis, identification of surface
markers and transmission electron microscopy. RNA was extracted and nine different micro-RNAs, related to hypoxia, PE and
Hb synthesis, were selected for analysis by quantitative PCR.
Results: All micro-RNAs investigated were present in the STBMs. Mir-517a, mir-141 and mir-517b were down regulated after
Hb perfusion in the 10K STBMs. Furthermore, Hb was shown to be carried by the STBMs.
Conclusion: This study showed that Hb perfusion can alter the micro-RNA content of released STBMs. Of particular interest
is the alteration of two placenta specific micro-RNAs; mir-517a and mir-517b. We have also seen that STBMs may function as
carriers of Hb into the maternal circulation.
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Introduction
Preeclampsia (PE) is a disorder that affects 2–7% of all
pregnancies [1] and is characterized by new onset hypertension
and proteinuria [2]. There is no method to predict the disorder
[1]. To date, the only cure is delivery and the treatment is purely
symptomatic [3]. PE is thought to develop in two stages; the first is
initiated by defective placentation resulting in inadequate forma-
tion of the utero-placental circulation. This results in an
inadequately perfused placenta, which causes reperfusion injury,
oxidative stress and formation of reactive oxygen species (ROS).
As a result of this, in the second stage, placenta derived factors are
released into the maternal circulation where they are believed to
cause systemic inflammation, endothelial damage and organ
failure [4].
Recently, cell-free foetal haemoglobin (HbF) was described to
be an important placenta derived factor, potentially linking the
first and second stage of PE. Analysis of placental gene expression
by Centlow et al. revealed that the haemoglobin (Hb) chains,
Hba2, Hbc and Hbb, were significantly up regulated in PE, and
an accumulation of HbF in the vascular lumen of PE placentas [5].
Also, perfusion of the placenta with cell-free Hb was shown to
induce structural damage similar to that seen in PE [6]. As both
HbF and its down-stream metabolites methaemoglobin, free heme
and ROS are potent redox agents that can cause tissue damage
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[7], it may be hypothesized that cell-free HbF plays a role in the
aetiology of PE by inducing oxidative damage to the blood-
placenta barrier [6]. Placenta derived factors, including HbF, then
leak into the maternal circulation where they are able to
contribute to oxidative stress, endothelial damage, inflammation,
hypertension and proteinuria [8,9]. Clinical studies have shown
that HbF leaks into the maternal circulation as early as the first
trimester and is increased in women that will subsequently develop
PE [10]. Furthermore, the levels of HbF correlates with the blood
pressure, i.e. the severity of the disease, in term pregnancies [8].
Programmed cell death leads to cell blebbing, causing apoptotic
debris, and extracellular vesicles (EVs) to be released [11].
Circulating EVs are often divided into apoptotic debris, micro-
vesicles (.100 nm) and exosomes (,100 nm), which in addition to
their size, differ regarding their membrane proteins and mode of
release [12–15]. The EVs are recognized as a form of cell-to-cell
communication that can transport proteins, DNA, RNA and
micro-RNA (miRNA) from one cell to another and alter the
phenotype and response of target cells [16–22].
The placental syncytiotrophoblast cells release EVs, named
syncytiotrophoblast vesicles or STBMs (previously called syncy-
tiotrophoblast microparticles). They have been suggested to be
important for the foetal-maternal cross talk, allowing the maternal
immune system to adapt to the on-going pregnancy [14,23]. The
role of STBMs in the aetiology of PE is an emerging field of
interest. The number of STBMs in maternal plasma increases
significantly in PE compared to normal pregnancies [9,16,24].
Placental perfusion with cell-free Hb increases blebbing of the cell
membranes suggesting an increased vesicle release [6]. Release of
apoptotic material into the maternal circulation has been
suggested to contribute to the endothelial dysfunction seen in PE
and increased numbers of STBMs to be involved in the
characteristic maternal inflammatory response [11,25–27]. For
example, studies have shown that STBMs isolated from perfused
placentas, when incubated with cultured monocytes, up regulate
CD54 and down regulate CD11a expression [26], and STBMs
incubated with cultured human umbilical vein endothelial cells
activate peripheral blood leukocytes [28], including both mono-
cytes [23] and neutrophils [29].
Micro-RNA (miRNA) are small non-coding RNA molecules
predicted to regulate approximately 30% of all human genes [30].
Gene expression is generally down regulated by miRNA, either by
degradation of the target mRNA or by preventing its translation
[31]. The miRNAs are important for the development and
function of the placenta. There is an abundance of miRNAs in the
placenta, originating from a large, primate-specific, genomic
cluster commonly referred to as the chromosome 19 miRNA
cluster (C19MC) [32,33]. C19MC miRNAs are differentially
expressed in trophoblastic cells, as well as placental tissue when
comparing first and third trimester placentas [34,35]. Placental
trophoblasts have been shown to release exosomes containing
miRNAs in general and to be enriched in miRNAs belonging to
C19MC in particular [32,33,36]. Both pregnancy specific [37] and
placenta-specific miRNA have been detected in maternal plasma
[36]. Many groups have also reported differentially expressed
miRNAs in PE and hypoxic placentas [38–41].
Previous work has described placental ex-vivo perfusion with cell-
free Hb as a model for PE [6]. The aim of this study was to further
investigate the harmful mechanisms of extracellular Hb, and to
examine the characteristics of STBMs released from placentas
perfused with cell-free Hb. In particular, we investigated the
miRNA content of released STBMs, following perfusion with cell-
free Hb. Nine interesting miRNAs were chosen for the study. We
selected mir-222, mir-16 and mir-210 based on previous studies
showing their involvement in the regulation of HbF expression
[42–44] as well as their involvement in PE [38–41]. Mir-517a,
mir-517b and mir-518b were chosen because of their placenta
specificity [36] and mir-518b being dys-regulated in PE [41]. Mir-
424 and mir-205 are altered in hypoxia [45] and mir-141 in PE
[39].
Materials and Methods
Ethics statement
The ethical review committee at Lund University approved the
study and all mothers gave their written informed consent before
delivery.
Placental perfusion and sample collection
Sample collection and dual ex-vivo perfusion of isolated human
placental cotyledons was performed as previously described by
May et al [6]. Briefly, the perfusion experiment consisted of three
perfusion phases lasting 120 minutes each, with medium exchange
between the phases. Perfusion medium was supplemented with
cell-free adult Hb (HbA) in the foetal circulation to mimic the PE
condition, during phase II (3 mg/ml HbA, n = 6) and medium
only in phase I and III. Control experiments were performed using
medium alone for all phases (n = 6). The perfusate was collected
from the maternal side at the end of all phases and used for
isolation and analysis of STBMs.
Isolation of STBMs from the perfusion medium
The STBM isolation was performed according to established
protocols [46] from phase I and II. Thirty five ml of the maternal
perfusate was centrifuged twice at 15006g for 10 minutes in order
to remove cellular debris. Ten ml of the supernatant was then
further centrifuged for 30 minutes at 10,0006g at 4uC (pellet
referred to as 10K STBM). The supernatant was ultra-centrifuged
for 2 hours at 150,0006g at 4uC (pellet referred to as 150K
STBM). The 10K and 150K STBM pellets were washed once with
1xPhosphate Buffered Saline (PBS) and re-suspended in 150 ml
and 50 ml PBS respectively, aliquoted and stored at 280uC.
Characterization of STBMs in the perfusion medium
Protein concentration of STBMs. The STBM protein
concentrations were determined spectrophotometrically using a
NanoDrop Spectrophotometer ND-1000 (NanoDrop technolo-
gies, Wilmington, USA).
Transmission electron microscopy (TEM) of
STBMs. Transmission electron microscopy (TEM) was per-
formed in two sets of preparations, first with antibodies against the
human proteins tissue factor (TF), CD 63 and hsa-mir-222, a
micro-RNA Assay primer (Applied Biosystems Inc., Foster City,
CA, USA), labelled with colloidal gold (30, 15 and 5 nm in
diameter, BBI International) as previously described [47]. In the
second preparation, antibodies against the human adult Hb (HbA)
protein was labelled with colloidal gold. The STBMs from both
the 10K and 150K fraction were mixed with gold-labelled
conjugates for 20 minutes at room temperature and then
processed for negative staining, as previously described [48]. It is
known that vesicles are permeabilized during TEM preparation,
allowing antibodies and probes to label targets both on the surface
and inside the STBMs. TEM was carried out three times in
different specimens for both control and Hb perfused STBMs.
Nanoparticle Tracking Analysis. Nanoparticle tracking
analysis (NTA) was performed using the NanoSight NS500
instrument (NanoSight, Amesbury, UK)[49]. This instrument
passes a focused 488 nm laser beam through a suspension of the
STBM miRNA Content after Haemoglobin Perfusion
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particles of interest and collects the scattered light using
conventional microscope optics aligned at 90u to the beam axis.
An electron multiplying charge coupled device captures a video of
the field of view at 30 frames per second. The NTA program
identifies and tracks Brownian motion of each particle from frame
to frame, thus enabling the calculation of the hydrodynamic
diameter via the Stokes-Einstein equation.
Samples analysed with NTA were from the different phase II
STBM preparations; 10K control STBM preparations (n = 6),
10K Hb (n = 6), 150K control (n = 6) and 150K Hb (n = 6). The
STBM preparations were diluted in sterile filtered PBS at 1:500 or
1:1000 prior to analysis, in order to give vesicle counts of 1.5–
9.06108/ml. The diluted sample was introduced into the sample
chamber and ten 20-second videos were recorded (shutter speed of
600; camera gain of 250). Fresh sample was introduced
automatically between each video recording to eliminate settling
and reduce sampling error. The videos were processed using
optimised instrument settings (detection threshold 10; blur
automatic; and minimum particle size 100 nm).
Analysis of miRNA in STBMs
RNA isolation. Small RNA was isolated from the10K and
150K STBMs using mirVanaTM miRNA Isolation Kit (Applied
Biosystems, Carlsbad, USA) according to manufacturer’s instruc-
tion. Briefly, the RNA extraction procedure consists of a step using
Acid-Phenol:Chloroform, separating RNA in an upper organic
phase from RNA and proteins which partitions in a lower aqueous
phase. This prevents the Hb protein from being present in the
RNA preparations and interacting in the subsequent PCR
procedure. All RNA sample concentrations were spectrophoto-
metrically determined using a NanoDrop Spectrophotometer ND-
1000 (NanoDrop technologies, Wilmington, USA). RNA quality
and miRNA content was assessed with an Agilent 2100
Bioanalyzer, using the Small RNA assay (Agilent Technologies,
Palo Alto, USA).
cDNA synthesis and real-time quantitative PCR. RNA
was transcribed using TaqManH MicroRNA Reverse Transcription
Kit according to manufacturer’s instructions (Applied Biosystems
Inc., Foster City, CA, USA). 10 ng RNA was used for the10K
STBMs. For the 150K STBMs, 5 ng RNA was used because of a
lower RNA yield. The following nine miRNAs were analysed using
pre-designed TaqManH MicroRNA assays (Applied Biosystems):
homo sapiens-microRNA-517b (hsa-mir-517b), hsa-mir-518b, hsa-
mir-222, hsa-mir-424, hsa-mir-210, hsa-mir-16, hsa-mir-141, hsa-
mir-205, hsa-mir-517a, Rnu6b. Sequence for the hsa-mir-517b
assay corresponds to ppy-mir-517b (pongo pygmaeus-microRNA,
according to the miRNA database mirbase.org), which differs two
nucleotides from the human hsa-mir-517b-3p.
Quantitative PCR (qPCR) was performed using standard
protocol supplied by manufacturer for TaqManH MicroRNA
Assays on an ABI PRISM 7000 sequence detection system
(Applied Biosystems). Primers and probes as described above.
Each reaction was run in duplicate. Negative controls with no
template as well as no reverse transcriptase controls were included
for every miRNA primer pair. Data were normalized to Rnu6b,
commonly used in miRNA PCR procedures. The fold-change
values were calculated by normalizing against control samples
from control perfused placentas placentas.
Statistical analysis
All statistical analysis was performed using Origin 9 software
(Microcal, Northampton, MA, USA). Mann-Whitney U-test was
used and p-value ,0.05 was considered statistically significant.
Results
Protein concentration and RNA content of the STBMs
After isolating the 10K and 150K STBMs, protein concentra-
tion was determined (Table 1). Protein concentration in the 10K
STBM controls was significantly higher than in the 150K STBM
controls (p = 0.0022). There was a slight difference, however not
significant, between 10K and 150K STBMs from the Hb
perfusions (p = 0.0649). No difference was found between control
and Hb perfusion in the 10K (p = 0.1320) or 150K STBMs
(p = 0.5887).
Analysis of the small RNA, with Agilent 2100 Bioanalyzer,
confirmed the presence of miRNA in all samples. The small RNA
concentrations (Table 1) in the two STBM fractions were
expressed either as RNA concentration (ng/ml) or amount of
RNA per mg of protein (RNA/STBM ratio) (Table 1). Clearly,
there was more RNA in the 10K STBM pellets compared to the
150K STBM pellets (p = 0.0022). No difference was seen between
the control and Hb perfusions within the same centrifugation
group. After calculating the RNA/STBM ratio, adjusting for size
and amount of STBMs, the levels of RNA appeared to increase
after Hb perfusion (Table 1). The RNA/STBM ratio was also
more variable after Hb perfusions compared to controls. However,
these results never reached statistical significance, p = 0.0649 for
10K and p = 0.1320 for 150K.
Characterization of STBMs
Transmission electron microscopy of STBMs. In order to
distinguish between different sizes and types of vesicles, STBMs
were investigated with transmission electron microscopy (TEM)
using CD63 as a marker for exosomes [14] and TF as a general
STBM marker [50] (Figure 1). Samples from both the 10K and
150K fractions as well as samples from both control and Hb
perfusions, contained vesicles that were marked with CD63, TF
and both (Table 2, and Figure 1B and 1C). There were no
Table 1. RNA and protein concentrations, as well as RNA/
STBM ratio.
Control Hb
Small RNA concentration (ng/ml)
Ph I 10K STBM 6,3566,42 1,6361,14
Ph II 10K STBM 17,366,48 16,8561,41
Ph I 150K STBM * *
Ph II 150K STBM 4,1463,01 7,4163,32
Protein concentration (mg/ml)
Ph I 10K STBM 3,1762,11 1,3460,91
Ph II 10K STBM 2,9661,55 1,7761,65
Ph I 150K STBM 0,7660,39 0,6760,21
Ph II 150K STBM 0,5560,33 0,6260,33
RNA/STBM ratio
Ph I 10K STBM 1,1961,32 2,4063,05
PhII 10K STBM 6,5262,30 15,9269,9
Ph I 150K STBM - -
Ph II 150K STBM 8,0463,88 14,0967,28
Values are expressed as mean 6 standard deviation.
* = immeasurable concentration by NanoDrop, RNA/STBM ratio not possible to
calculate.
doi:10.1371/journal.pone.0090020.t001
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significant differences between the 10K and 150K fraction when
comparing the four markers CD63, TF, Hb and mir-222. The
CD63 and TF markers did not differ between controls and Hb
STBMs. However, the analysis of the gold signal for mir-222
displayed a down regulation after Hb perfusion (Table 2, and
Figure 1B and 1C). Also, mir-222 labelling was found in vesicles
expressing both CD63 and TF. Interestingly, in a subsequent
preparation with gold-labelling of Hb antibodies, TEM revealed
that STBMs carried Hb, and vesicles isolated from Hb perfusions
carried more Hb than vesicles from the control perfusions (Table 2,
and Figure 1D and 1E).
Nanoparticle Tracking Analysis. To determine the vesicle
count and size distribution of vesicles in the 10K and 150K
STBMs, we used the NTA methodology. Vesicle count broadly
reflected the protein concentration of the 10K STBM preparations
(r = 0.71) with stronger correlation in the 150K preparations
(r = 0.95). This was probably due to the greater homogeneity
observed in the 150K preparations. The size distribution for 10K
and 150K STBMs ranged between 50–560 nm and 50–500 nm
respectively (Figure 2A and 2B) The size range suggests that both
STBM preparations contain both exosomes and microvesicles.
There was no difference in this range between the controls and the
Hb perfusions. The median size for 10K control was 184 nm and
for Hb STBMs 187 nm (Figure 2A). For 150K control and Hb
STBMs the median size was 171 nm and 166 nm respectively
(Figure 2B). The median size was significantly larger for the 10K
STBMs (186 nm) compared to the 150K STBMs (168 nm), shown
in Figure 2C. This suggests that the 10K STBMs contain more
STBMs in the microvesicle size range and fewer in the exosomes
size range.
Analysis of miRNAs in STBMs
All miRNAs (mir-517a, mir-517b, mir-518b, mir-205, mir-210,
mir-222, mir-141, mir-16 and mir-424) analysed in this study were
present in both 10K and 150K STBMs. After Hb perfusion, mir-
517a (p = 0.03671), mir-141 (p = 0.01219) and mir-517b
(p = 0.03671) were significantly down regulated in 10K STBMs
(Figure 3). To confirm that the differences obtained between the
groups were dependent on Hb perfusion, mir-141 and mir-517a
were also analysed in phase I, before addition of Hb. There was no
significant difference (p = 0.27034 and 0.17791 respectively) in
phase I. In contrast, the 150K STBMs showed a general trend
towards up-regulation of miRNA after Hb perfusion, although
none were significant (data not shown).
Discussion
Extracellular HbF has been suggested as a potential link
between the first and second stage of PE [5,10]. Ex-vivo studies
have shown that cell-free Hb induces placental damage similar to
that seen in PE placentas, and therefore might provide an
experimental ex-vivo model for PE. Electron microscopy showed
that cell-free Hb causes oxidative stress, apoptosis and extensive
membrane damage to perfused placentas [6]. In this study, we
have further investigated the perfusion medium from these
experiments in order to see how cell-free Hb affects the release
of STBMs and their miRNA content. The data show that Hb
Figure 1. Transmission electron micrographs of isolated
STBMs. The TEM panel (A) shows a selection of the 150K control
STBMs, prior to gold-labelling. The STBMs were mixed with gold-
labelled antibodies, as described in the Materials and Methods section,
in two preparations. In the first preparation, STBMs shown in panels (B,
control) and (C, Hb perfusions), were treated with antibodies against TF,
CD63 and hsa-mir-222 labelled with colloidal gold of different sizes;
CD63 (30 nm colloidal gold), TF (15 nm) and mir-222 (5 nm). Panel (B)
shows the 150K control STBMs which are similar to the 150K Hb STBMs
(C) in regards to the number of vesicles and their size. The 150K control
STBMs (B) contain more mir-222 than 150K Hb STBMs (C). For the
second preparation, STBMs shown in panels (D, control) and (E, Hb
perfusions), were treated only with antibodies against Hb, labelled with
colloidal gold. Control STBMs (D) carried small amounts of Hb, whereas
STBMs from the Hb perfused placentas (E) showed higher labelling for
Hb on particles of all sizes.
doi:10.1371/journal.pone.0090020.g001
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perfusion indeed does alter the content of miRNAs in STBMs.
Since perfusion with Hb leads to increased cell blebbing [6] we
also hypothesized that the placenta released more STBMs, as
described in PE [9,16,24]. However the NTA analysis could not
confirm this hypothesis. An unexpected and interesting finding
was however that the STBMs carried Hb, possibly inside but also
on the surface.
The different STBM fractions, showed a decreased median
vesicle size in the 150K STBMs compared to the 10K STBMs,
confirming earlier results [46]. This suggests more vesicles in the
exosome size range (,100 nm) and fewer of microvesicle size
range (.100 nm) after higher centrifugation speed. The two
surface markers TF and CD63 used in TEM, showed a similar
distribution between the two centrifugation fractions. In contrast
to the NTA analysis, this finding suggest that there is no major
differences between the types of vesicles isolated at different
centrifugation speeds. However, even though the surface marker
CD63 has been suggested to be a specific exosomes marker [14], it
has also been found on the syncytiotrophoblast surface [51],
indicating that it is likely to be present on the microvesicles
released by syncytiotrophoblasts. The TEM showed that STBMs,
larger than 100 nm, were positive for CD63, confirming this. The
TF marker was also shown on vesicles of all sizes confirming
previous findings [50].
Although there were no obvious differences in the STBM
characteristics between control and Hb perfused placentas, we
found significant differences in their miRNA content. The nine
selected miRNAs were related to the C19MC cluster, hypoxia, PE
or Hb synthesis [36,38–45].
Three miRNAs were down regulated in the 10K STBMs after
Hb treatment; mir-517a, mir-141 and mir-517b. Mir-141 is one of
the most abundant miRNAs in the placenta and found in high
levels in maternal plasma during pregnancy [52,53]. Mir-517a and
mir-517b belong to the C19MC cluster [32]. The C19MC
miRNAs have previously been shown to be transported by
trophoblast exosomes [32,36]. Recently it has been shown that
mir-517b can be transported by trophoblast exosomes to recipient
cells, normally not expressing C19MC miRNAs, and inhibit viral
infections [54]. By sending out placenta specific miRNAs, the
placentas may communicate to the maternal system. By altering
the miRNA content in the STBMs, different signals can be sent to
the receiving cells.
The TEM analysis showed that mir-222 was down regulated in
both 10K and 150K STBMs. This was not confirmed by
quantitative PCR, possibly due to small groups. There is an
interesting connection between mir-222 and PE, it has been shown
to be up-regulated in the PE placenta [38–41] but also present in
circulating EVs from healthy controls [55]. To our knowledge, no
previous studies have described mir-222 in STBMs. The mir-222
regulates fms-like tyrosine kinase-1 (Flt1) [43], which is an anti-
angiogenic factor, well described in PE [4]. Furthermore, mir-222
plays a role in the human haemoglobin switch, i.e. when the
newborn baby switches from HbF to HbA production, which takes
place during the peri/post-natal period [43]. Since previous data
have shown an increased production of HbF in PE placentas [5],
Table 2. Transmission electron microscopy (TEM) data, showing the amount of gold labels per square micrometre.
10K STBM Control 10K STBM Hb 150K STBM Control 150K STBM Hb
TF 46616 58615 52613 63615
CD63 31612 44615 2869 41618
mir-222 98614 52617 96615 63616
Hb 963 49617 1063 51617
Values are expressed as mean 6 standard deviation.
doi:10.1371/journal.pone.0090020.t002
Figure 2. NTA analysis of vesicle size distribution in the 10K and 150K fraction. Nanoparticle tracking analysis (NTA) size distribution
profiles for STBMs; comparing effect of Hb perfusion for 10K (A) and 150K (B) STBMs. In (C) the effect of centrifugation speed, 10K vs 150K, is
compared. 10K STBMs had a significantly larger median size than 150K STBMs.
doi:10.1371/journal.pone.0090020.g002
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and elevated levels of s-Flt [4], the role of mir-222 needs further
exploration.
The 150K STBMs did not show any significant changes in the
miRNA content for the nine miRNAs studied. Data from the
NTA analysis suggest that the 150K fractions contain smaller
STBMs, and possibly therefore more exosomes. Since exosomes
are released by exocytosis and microvesicles by blebbing of the cell
surface [12], it may be likely that they load RNA and miRNA in
different ways. It has been suggested that exosomes are beneficial
to normal pregnancy whereas microvesicles may be harmful [56].
When comparing different trophoblastic cells and cell lines, a
previous study has shown great variation of miRNA expression, in
particular C19MC miRNAs, which may account for the
differences in behaviour between these cells [34]. The differences
in miRNA expression between the 10K and 150K fractions might
be part of the explanation of why exosomes and microvesicles play
different roles in normal pregnancies and in PE. Even though Hb
treatment does not alter the shedding of vesicles from the human
placenta, the data shows that miRNA content can be significantly
altered. This could suggest that Hb has an effect at the level of
gene expression. On the other hand, there was a trend towards a
generally impoverished miRNA content in 10K STBMs and
enriched miRNA content in 150K STBMs. Rather than having an
effect on a transcriptional level in the cells, Hb could be changing
the profile of STBMs carrying miRNAs where exosomes increase
their miRNA content during stress and microvesicles decrease
theirs.
The TEM results indicated that cell-free Hb was accumulated
inside or on the surface of the STBMs. The small amount of Hb
present in the control STBMs, may be due to the natural Hb
metabolism occurring in the placenta. During Hb perfusion there
is a high Hb concentration outside the vesicles, which may cause
binding to the surface. It is important to note that the Hb antibody
used for the specific TEM, targets the alpha-chain and therefore
measures total Hb, both the Hb added to the perfusion as well as
the endogenous foetal production in the placenta. These findings
suggest a novel way for Hb to be transferred into the maternal
circulation from the placenta, and will be subject for future studies.
In summary, the data in this study suggest that Hb perfusion of
the placenta significantly affects the content of some miRNAs in
released STBMs. The increased amount of STBMs in PE may be
potentially loaded with Hb and differentially expressed miRNAs,
which will have negative effects on target cells such as endothelial
cells and lymphocytes. It may contribute to the endothelial
dysfunction and inflammation seen in PE [4]. STBMs may be
important for communicating the status of the placenta system-
ically. Accumulation of Hb in STBMs may prevent Hb from being
degraded. Upon fusion with other cell types, a direct intracellular
deposit of Hb may cause toxic damage. Accumulated Hb may also
oxidize the STBMs content, modifying RNA and proteins, which
could have further impact on the vesicle-to-cell signalling.
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